Fred Alger Management’s Krystal Biotech KRYS Stock Holding History

Fred Alger Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.01M	Buy	+5,418	New	+$1.62M	0.01%	319
2025 Q2	–	Sell	-3,728	Closed	-$672K	–	462
2025 Q1	$672K	Buy	+3,728	New	+$627K	﹤0.01%	345
2024 Q1	–	Sell	-160,335	Closed	-$19.9M	–	473
2023 Q4	$19.9M	Sell	160,335 -7,150	-4%	-$793K	0.11%	140
2023 Q3	$19.4M	Buy	167,485 +163,928	+4,609%	+$20M	0.11%	146
2023 Q2	$418K	Buy	+3,557	New	+$363K	﹤0.01%	405

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fred Alger Management's KRYS Position: Q2 2026 in Review

Fred Alger Management opened a new position in Krystal Biotech (KRYS) in Q2 2026: 5,418 shares worth $2.01M. The stake represents 0.01% of the portfolio and ranks #319 among its holdings. This is a return to the name: Fred Alger Management previously reported a position in KRYS as recently as Q1 2025.

Fred Alger Management first reported a position in KRYS in Q2 2023 and has held it in 5 quarters since. The position peaked at $19.9M in Q4 2023. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Fred Alger Management held 5,418 shares of Krystal Biotech worth $2.01M as of Q2 2026.
Krystal Biotech was a new Fred Alger Management position in Q2 2026.
Krystal Biotech made up 0.01% of Fred Alger Management's portfolio in Q2 2026, its #319 holding.
Fred Alger Management first reported a position in Krystal Biotech in Q2 2023 and has held it in 5 quarters since.
Fred Alger Management's Krystal Biotech position peaked at $19.9M in Q4 2023.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.